|
시장보고서
상품코드
2008070
칼슘 채널 차단약 시장 : 약제 클래스별, 적응증별, 유통 채널별, 지역별Calcium Channel Blocker Drugs Market, By Drug Class, By Disease Indication, By Distribution Channel, By Geography |
||||||
칼슘 채널 차단약 시장은 2026년에 174억 6,060만 달러로 추정되고 있으며, 2033년까지 248억 5,740만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 5.2%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 174억 6,060만 달러 |
| 실적 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년의 예측 기간 CAGR : | 5.20% | 2033년 시장 규모 예측 : | 248억 5,740만 달러 |
칼슘 채널 차단제는 고혈압, 부정맥이라고 불리는 심장 박동 장애, 협심증과 관련된 흉통을 치료하는 데 사용되는 약물의 일종입니다. 이들은 심장과 동맥으로 들어가는 칼슘의 일부를 차단하는 방식으로 작용합니다. 칼슘 채널 차단제는 속효성 용해 정제부터 서방형 캡슐까지 다양한 제형이 있습니다. 복용량은 환자의 전반적인 건강 상태와 병력에 따라 다릅니다.
또한 만성콩팥병은 수년간 서서히 신장 기능이 저하되는 질환입니다. 신부전이 진행되어 장기 기능이 심각하게 손상되면 체내에 위험한 수준의 노폐물과 체액이 빠르게 축적될 수 있습니다. 치료의 목적은 질병의 진행을 막거나 지연시키는 것이며, 보통 근본적인 원인을 관리함으로써 이루어집니다. 칼슘 채널 차단제는 만성 신장 질환 또는 그 근본적인 원인을 치료하는 데 사용되는 약물입니다.
시장 역학
심혈관 질환, 비만, 건강에 해로운 생활습관의 유병률 증가는 예측 기간 중 시장 성장을 촉진할 것으로 예상됩니다.
예를 들어 세계보건기구(WHO)의 2022년 보고서에 따르면 2019년 심혈관 질환으로 인한 사망자 수는 1,790만 명으로 추정되며, 그 중 85%는 전 세계에서 심근경색과 뇌졸중으로 인한 사망입니다.
칼슘 채널 차단제의 신규 승인 및 승인 증가로 인해 예측 기간 중 시장이 크게 성장할 것으로 예상됩니다.
예를 들어 2022년 6월 CMP Pharma, Inc.는 6세 이상 환자에서 고혈압 치료를 위한 장시간 지속형 칼슘 채널 차단제인 암로디핀베실산염 경구용 액제 'Norliqva(암로디핀) 경구용액 1 mg/mL'에 대해 미국 식품의약국(FDA)의 승인을 받았습니다. (FDA)의 승인을 취득했습니다.
본 조사의 주요 특징
- 이 보고서는 2025년을 기준연도로 하여 예측 기간(2026-2033년)의 글로벌 칼슘 채널 차단제 시장, 시장 규모, 연평균 성장률(CAGR)에 대한 상세한 분석을 전해드립니다.
- 이 보고서는 각 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요 인사이트도 제공합니다.
- 이 보고서에서는 회사 개요, 제품 포트폴리오, 주요 특징, 재무 성과 및 전략과 같은 매개 변수를 기반으로 세계의 칼슘 채널 차단제 시장의 주요 기업을 프로파일링합니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 이 세계의 칼슘 채널 차단제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가를 포함한 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 칼슘 채널 차단제 시장 분석에 사용된 다양한 전략 매트릭스를 활용하여 의사결정을 원활하게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 칼슘 채널 차단약 시장 : 약제 클래스별, 2026-2033년
제5장 세계의 칼슘 채널 차단약 시장 : 적응증별, 2026-2033년
제6장 세계의 칼슘 채널 차단약 시장 : 유통 채널별, 2026-2033년
제7장 세계의 칼슘 채널 차단약 시장 : 지역별, 2026-2033년
제8장 경쟁 구도
제9장 섹션
KSA 26.04.30Calcium Channel Blocker Drugs Market is estimated to be valued at USD 17,460.6 Mn in 2026 and is expected to reach USD 24,857.4 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 17,460.6 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.20% | 2033 Value Projection: | USD 24,857.4 Mn |
Calcium channel blockers are class of medicines used for the treatment of hypertension, irregular heartbeats called arrhythmias and chest pain related to angina they work by blocking some of the calcium that enters the heart and arteries. Calcium channel blocker drugs are available in many forms which ranging from short-acting dissolving tablets to extended-release capsules. The dosage will depend on overall health and medical history of patients.
Moreover, chronic kidney disease is the progressive loss of kidney function over a period of several years. As kidney failure advances to further stages, and the organ's function is severely impaired, dangerous levels of waste and fluid can rapidly build up in the body. Treatment is aimed at stopping or slowing down the progression of the disease - this is usually done by controlling its underlying cause calcium channel blockers are drug used in the treatment of chronic kidney disease or its underlying cause.
Market Dynamics
Increasing prevalence of cardiovascular disease, obesity, unhealthy life style is expected to drive the market growth during the forecast period.
For instance, according to the World Health Organization 2022, an estimated 17.9 million people are died from cardiovascular disease in 2019 form which 85% death are occur due to heart attack and stroke worldwide.
Increasing lunches and approval of calcium channel blocker drug is expected to witness significant growth of the market over the forecast period
For instance, in June 2022, CMP Pharma, Inc., a pharmaceutical company receive the U.S. Food and Drug Administration approval for its Norliqva (amlodipine) oral solution, 1 mg/mL, an oral liquid solution of the besylate salt of amlodipine, a long-acting calcium channel blocker for the treatment of hypertension in patients 6 years of age and older.
Key features of the study
- This report provides an in-depth analysis of the global calcium channel blocker drugs market, market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global calcium channel blocker drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Bausch Health, Mylan N.V., Teva Pharmaceutical Industries Ltd, Lupin, Arbor Pharmaceuticals, GlaxoSmithKline Plc, Biopharma, Sofgen Pharmaceuticals, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Novartis AG, Zydus Cadila and Pfizer Inc,
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global calcium channel blocker drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global calcium channel blocker drugs market
Market Segmentation
- Global Calcium Channel Blocker Drugs Market, By Drug Class
- Benzothizepine
- Dihydropyridine
- Phenylalkylamine
- Global Calcium channel blocker drugs market, By Disease Indication
- Hypertension
- Chest Pain
- Arrhythmias
- Others (Blood vessel conditions, Coronary Artery Disease etc.)
- Global Calcium Channel Blocker Drugs Market, By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Global Calcium Channel Blocker Drugs Market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players
- Bausch Health
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd
- Lupin
- Arbor Pharmaceuticals
- GlaxoSmithKline Plc
- Biopharma
- Sofgen Pharmaceuticals
- Glenmark Pharmaceuticals Inc.
- Amneal Pharmaceuticals
- Sun Pharmaceutical Industries Ltd
- Novartis AG
- Zydus Cadila
- Pfizer Inc
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Key Development Strategies
- Mergers And Acquisition Scenario
- Market Trends
- Brand Analysis
- Regulatory Scenario
- PEST Analysis
- Pricing Analysis
4. Global Calcium Channel Blocker Drugs Market, By Drug Class, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026-2033
- Segment Trends
- Benzothizepine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Dihydropyridine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Phenylalkylamine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
5. Global Calcium Channel Blocker Drugs Market, By Disease Indication, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026-2033
- Segment Trends
- Hypertension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Chest Pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Arrhythmias
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Others (Blood vessel conditions, coronary artery disease etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
6. Global Calcium Channel Blocker Drugs Market, By Distribution Channel, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026-2033
- Segment Trends
- Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
- Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
7. Global Calcium Channel Blocker Drugs Market, By Region, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2033
- North America
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Region/Country, 2026 - 2033, (USD Mn)
- South Africa
- Central Africa
- North Africa
8. Competitive Landscape
- Competitive Snapshot
- Bausch Health
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Mylan N.V.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Teva Pharmaceutical Industries Ltd
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Lupin
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Arbor Pharmaceuticals
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GlaxoSmithKline Plc
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Biopharma
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sofgen Pharmaceuticals
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Glenmark Pharmaceuticals Inc
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Amneal Pharmaceuticals
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sun Pharmaceutical Industries Ltd,
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Novartis AG
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Zydus Cadila
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Pfizer Inc,
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
9. Section
- References
- Research Methodology
- About us and Sales Contact
